Biomedical subjects

L Krivan

Publications and source records attributed to L Krivan.

6 recordsLinked to original sources

PubMed2005

[Comparison of the prevalence of non-invasive risk markers of the sudden cardiac death in patients treated by thrombolysis and by percutaneous transluminal coronary angioplasty].

BACKGROUND: Myocardial infarction survivors may develop a higher risk of sudden cardiac death. The risk markers: left ventricular ejection fraction, ventricular premature beats, late potentials on averaged ECG, baroreflex sensitivity and heart rate variability are used as non-invasive stratification markers. METHODS AND RESULTS: Occurrence of the autonomic and morphologic dysfunction risk markers in the myocardial infarction patients treated by thrombolysis and by primary percutaneous transluminal coronary angioplasty (PTCA) is compared. We studied a cohort of 48 acute myocardial infarction survivors treated by primary PTCA and 96 patients treated by thrombolysis. CONCLUSIONS: Patients treated by primary PTCA had significantly lower occurrence of premature ventricular beats and pathological parameters of the heart rate variability.

Angioplasty, Balloon, Coronary↗

PubMed2004

[Care of patients with implanted cardioverters-defibrillators: what every physician should know].

Implantable cardioverter defibrillators have become an integral part of treatment of patients with malignant chamber arrhythmias over last 10 years both in secondary and primary prevention of sudden deaths. Based on monitoring of a group of 182 patients and based on information in literature, authors present a survey of the most frequent situations, rules and complications related to therapy with implantable defibrillators. In the end they try to answer summary of the most frequent questions of internal medicine physicians and GPs concerning patients with this implanted device.

Arrhythmias, Cardiac↗

PubMed2004

[Specific complications in the treatment with implantable cardioverter-defibrillators].

BACKGROUND: Using implantable cardioverter-defibrillators in treatment of malignant ventricular arrhythmias revealed new complications specific to this therapy. Inappropriate therapy, arrhythmic storm and device related proarrhythmia belong to the most significant complications. The authors describe specific complications in a group of ICD patients, analyze their etiology and prognostic value. There are some recommendations for the management of specific complications. METHODS AND RESULTS: 138 consecutive patients underwent ICD implantation between 1994-2001. Median follow-up was 47,35 months. Average left ventricular ejection fraction was 38 +/- 14% and 71% of patients suffered from coronary artery disease. From the total of 2490 arrhythmic episodes 1490 were evaluated in detail. 253 episodes (17%) were classified as inappropriate therapy. The most common etiology of inappropriate therapy was atrial fibrillation with rapid ventricular response (68%), atrial flutter (13%) and sinus tachycardia (11%). After the therapeutic intervention, 65% of them remained free of inappropriate therapy. There were 38 arrhythmic storms in 19 patients as another serious complication. CONCLUSIONS: All the observed arrhythmic episodes were ventricular tachycardias (p<0.04). Patients with arrhythmic storm in history had significantly lower survival (p<0.05). The risk factors of cardiac nonsudden death were: age >66 years, left ventricular ejection fraction <35% and arrhythmic storm history. The authors present recommendations for the treatment of the most common specific ICD complications.

Adult↗

PubMed2001

[Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].

The aim of this work is to characterize and analyse the spectrum of therapies delivered from implantable cardioverter-defibrillators (ICD), to evaluate their effectivity and to mark the most effective types of antitachycardia stimulations (ATP), cardioversion (CV) and defibrillation (CD). To compare our results with references and give precautions of trouble-shootings. Our patients had implanted ICDs according to standard criteria for ICD implantations. Before discharge from hospital we performed predischarge test of their ICD. Than we followed them periodically each three months. We have observed 72 ICD pts (55 M, 17 F) in the mean age of 62.7 +/- 12.2 years the with mean LVEF was 0.37 +/- 0.11. The mean follow-up was 21 +/- 12.8 months. Each examination was managed through anamnesis of symptoms accompanying the beginning of arrhythmia, the sensation of ICD therapy by patient, followed by interrogation of the ICD memory. All obtained episodes were analysed. During the follow-up 1023 episodes of malignant ventricular arrhythmias were detected and effectively terminated. 7 pts died. During the therapy the ATP reached 83% in comparison with CV, CD which reached only 17%. The dominating symptoms were palpitations and presyncopes. In comparison with initial arrhythmias leading to implantations of ICDs (ventricular fibrillations for most of the cases--54%) the significantly higher number of spontaneous episodes were caused by monomorphic ventricular tachycardias VT (92.0%). We had no sudden cardiac death in our pts. In the indicated pts with a high risk of sudden arrhythmic death, the ICD therapy is characterized as very effective and is associated with high safety, low discomfort and when up to date algorithms for detection being used, then only adequate part of the inappropriate therapies occurs (10% patients, 3.2% from the number of episodes). The therapy by implantable cardioverter-defibrillators has had an important role in treating pts with life-threatening ventricular arrhythmias.

Adult↗

PubMed1997

[Selection and long-term effect of treatment in vasovagal neurocardiogenic syncope].

BACKGROUND: Syncope state performed by transient loss of consciousness connected with a postural tone decrease present still an important therapeutical problem. The authors use HUT testing for discovering of vasovagal etiology of a syncope. The aim of the study was to find out the optimal medication in treatment and prevention of VVS by repeated HUT drug testing in a group of positive patients. METHODS AND RESULTS: We examined a group of 300 patients (172 female and 128 male) age 35.26 +/- 13.47 years with an anamnesis of recurrent syncopes by HUT test. In 83 patients (27%) we set up a diagnosis of VVS. Thirteen patients (15.66%) were only followed without medication. The rest of the group (70 patients, 84.34%) started with a therapy. Testing was performed by repeated HUT according to the "Westminster protocol". HF and BP were measured by FINAPRESS 2,300 made by Ohmeda. The effective therapy was found in 64 patients (91.43%) of the group. For various reasons the therapy was changed and retested in 9 patients (14.06%). Beta1 selective beta-blockers were used in 51 patients (80.96%) theophyllin in 5 patients (7.94%), etilephrin in 6 patients (9.52%) and clonidine in 1 patient (1.59%). CONCLUSIONS: The therapy of VVS should be set-on according to the effective drug selection by serial drug testing in repeated HUT tests. The article shows a high predictive value of negative HUT test for a long term effect of tested therapy.

Adult↗

PubMed1995

[Neural syncope--a current therapeutic problem].

Syncope, a state performed by transient loss of consciousness connected with postural tone decrease present still an important therapeutical problem. It can vary from a benign physiological body reaction to a life-limiting situation. The authors of the article present HUT-testing to be a simple, useful and safe method for discovering vasovagal mechanism of the syncope. They notice the experiences with treatment according to the HUT results. The most frequent types of therapy are the pharmacological and the pacing ones, when the former is appropriate for I and III class of VVS the latter then for the II. class. There are some big studies in progress now which should bring more information about this clinical problem.

Humans↗